Skip to content
sellModerate cluster of 510b5-1 plan

Pushkal Garg sold $2.7M of ALNY

EVP Chief R&D at ALNYLAM PHARMACEUTICALS, INC.. 5,959 shares at an average of $451.76, traded Oct 2, 2025, filed Oct 3, 2025.

Warning score
40
Value
$2.7M
5,959 shares
Holdings after
20,221
-23% from before
From 52-week low
+106%
low $224.32, close $460.99
From 52-week high
-4%
high $482.13, as of Oct 2, 2025

Score components

  • Role
    Officer
    +15
  • Trade size
    $2.7M at market
    +25
  • Share of holdings sold
    Sold 23% of holdings
    +5
  • Cluster
    5 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

This signal so far: 1m -0.1%, 3m -12.3%, 6m -30.1%.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ALNYOct 9, 2026 · close 232.68
Since filing Oct 3, 2025: -49.0%SPY +17.6% · excess -66.6%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0001735276-25-000113, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Oct 1, 2025AGrant or award
Common Stock10b5-1
+3,108$0.00$023,329Oct 3, 2025
Oct 1, 2025AGrant or award
Common Stock10b5-1
+2,851$0.00$026,180Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-115$446.53$51k26,065Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-56$447.92$25k26,009Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-180$448.77$81k25,829Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-249$449.79$112k25,580Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-541$450.81$244k25,039Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-332$451.86$150k24,707Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-668$452.69$302k24,039Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-329$453.77$149k23,710Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-244$454.84$111k23,466Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-73$455.82$33k23,393Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-147$457.43$67k23,246Oct 3, 2025
Oct 2, 2025SOpen-market sale
Common Stock10b5-1
-3$457.64$1,37323,243Oct 3, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-682$449.99$307k22,561Oct 3, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-810$450.63$365k21,751Oct 3, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-898$451.76$406k20,853Oct 3, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-417$453.51$189k20,436Oct 3, 2025
Oct 3, 2025SOpen-market sale
Common Stock10b5-1
-215$454.37$98k20,221Oct 3, 2025

Related signals

Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
36Weak
ALNYsell
ALNYLAM PHARMACEUTICALS, INC.
Bryan Supran
EVP, CLO and Secretary
$399k
1,758 shares
-12%
25Weak
ALNYsell10b5-1
ALNYLAM PHARMACEUTICALS, INC.
David E I Pyott
director
$1.1M
3,830 shares
-71%
30Weak
ALNYsell10b5-1
ALNYLAM PHARMACEUTICALS, INC.
Melissa McLaughlin
Chief Human Resources Officer
$1.3M
3,910 shares
-29%
26Weak
ALNYsell 510b5-1
ALNYLAM PHARMACEUTICALS, INC.
Kevin Joseph Fitzgerald
CSO & EVP, Head of Research
$418k
1,291 shares
-6%
51Moderate
ALNYsell 5
ALNYLAM PHARMACEUTICALS, INC.
Tolga Tanguler
EVP, Chief Commercial Officer
$746k
2,309 shares
-6%
59Moderate
ALNYsell 5
ALNYLAM PHARMACEUTICALS, INC.
Jeffrey V. Poulton
EVP, Chief Financial Officer
$797k
2,468 shares
-4%
64Notable
ALNYsell 5
ALNYLAM PHARMACEUTICALS, INC.
Yvonne Greenstreet
Chief Executive Officer
$948k
2,933 shares
-3%
40Moderate
ALNYsell 510b5-1
ALNYLAM PHARMACEUTICALS, INC.
Pushkal Garg
EVP Chief R&D
$1.5M
4,713 shares
-20%
65Notable
ALNYsell 5
ALNYLAM PHARMACEUTICALS, INC.
Yvonne Greenstreet
Chief Executive Officer
$2.2M
6,799 shares
-6%
48Moderate
ALNYsell 5
ALNYLAM PHARMACEUTICALS, INC.
Tolga Tanguler
EVP, Chief Commercial Officer
$524k
1,598 shares
-4%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Pushkal Garg sold $2.7M of ALNY | InsiderTell